Evidence map›Paper›PMID 33219877›Full record

ArticleAIDS and behavior2021

Design and Delivery of Real-Time Adherence Data to Men Who Have Sex with Men Using Antiretroviral Pre-exposure Prophylaxis via an Ingestible Electronic Sensor.

Peter R Chai, Georgia Goodman, Majo Bustamante, Lizette Mendez, Yassir Mohamed, Kenneth H Mayer, Edward W Boyer, Rochelle K Rosen, Conall O'Cleirigh

Open access · greenAbstract read
In one paragraph

Article in AIDS and behavior, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
0.5field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Real-World Implementation Challenges Associated with a Digital Pill System to Measure Adherence to HIV Pre-Exposure Prophylaxis from Two Studies of Men Who Have Sex With Men.Proceedings of the ... Annual Hawaii International Conference on System Sciences. Annual Hawaii International Conference on System Sciences · 2024
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Peter R ChaiDivision of Medical Toxicology, Department of Emergency Medicine, Brigham and Women's Hospital, 75 Francis St, Boston, MA, 02411, USA. pchai@bwh.harvard.edu.ORCID http://orcid.org/0000-0003-0955-4117
Georgia GoodmanThe Fenway Institute, Fenway Health, Boston, MA, USA.
Majo BustamanteThe Fenway Institute, Fenway Health, Boston, MA, USA.
Lizette MendezThe Fenway Institute, Fenway Health, Boston, MA, USA.
Yassir MohamedThe Fenway Institute, Fenway Health, Boston, MA, USA.
Kenneth H MayerThe Fenway Institute, Fenway Health, Boston, MA, USA.
Edward W BoyerDivision of Medical Toxicology, Department of Emergency Medicine, Brigham and Women's Hospital, 75 Francis St, Boston, MA, 02411, USA.
Rochelle K RosenCenter for Behavioral and Preventive Medicine, The Miriam Hospital, Providence, RI, USA.
Conall O'CleirighThe Fenway Institute, Fenway Health, Boston, MA, USA.
Fenway Health · USBrigham and Women's Hospital · USBeth Israel Deaconess Medical Center · USBrown University · USHarvard University · US

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ARTHUR Y KIM · 2004 to 2026
$94.4M
Harvard Medical School Vaccine Clinical Trials UnitUM1AI069412 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI Lindsey Robert Baden, Daniel R. Kuritzkes · 2012 to 2026
$57.2M
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH, DEBBIE M. CHENG · 1998 to 2026
$51.7M
MyTPill: A Novel Strategy to Monitor Antiretroviral Adherence among HIV+ Prescription Opioid UsersR01DA047236 · NIDA · OHIO STATE UNIVERSITY · PI BOYER, EDWARD W, CARRICO, ADAM WAYNE · 2019 to 2022
$3.0M
A novel robotic wastewater analysis system to quantify opioid exposure and treatment in residential communitiesR44DA051106 · NIDA · BIOBOT ANALYTICS, INC. · PI CHAI, PETER R, MATUS GARCIA, MARIANA G · 2020 to 2022
$1.5M
Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance UsersK23DA044874 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · PI CHAI, PETER R · 2018 to 2022
$1.0M
NIDA National Early Warning System Network (iN3): An Innovative ApproachR56DA038366 · NIDA · WRIGHT STATE UNIVERSITY · PI BOYER, EDWARD W, CARLSON, ROBERT GEOFFREY · 2014 to 2014
$300k
Gilead Sciences ISR-17-10189National Institute of Allergy and Infectious Diseases P30AI060354NIAID NIH HHS P30 AI042853NIAID NIH HHS P30 AI060354NIAID NIH HHS UM1 AI069412NIDA NIH HHS K23 DA044874NIDA NIH HHS K23DA044874NIDA NIH HHS R01 DA047236NIDA NIH HHS R01DA047236NIDA NIH HHS R44 DA051106NIDA NIH HHS R44DA051106NIDA NIH HHS R56 DA038366
6 · The paper itself

Abstract

Once daily tenofovir/emtricitabine when used for pre-exposure prophylaxis (PrEP) is effective in preventing HIV acquisition but requires consistent medication adherence. The use of ingestible technologies to monitor PrEP adherence can assist in understanding the impact of behavioral interventions. Digital pill systems (DPS) utilize an ingestible radiofrequency emitter integrated onto a gelatin capsule, which permits direct, real-time measurement of medication adherence. DPS monitoring may lead to discovery of nascent episodes of PrEP nonadherence and allow delivery of interventions that prevent the onset of sustained nonadherence. Yet, the acceptance and potential use of DPS in high-risk men who have sex with men (MSM; i.e., those who engage in condomless sex and use substances) is unknown. In this investigation, we conducted individual, semi-structured qualitative interviews with 30 MSM with self-reported non-alcohol substance use to understand their responses to the DPS, willingness and perceived barriers to its use, and their perceptions of its potential utility. We also sought to describe how MSM would potentially interact with a messaging system integrated into the DPS. We identified major themes around improved confidence of PrEP adherence patterns, safety of ingestible radiofrequency sensors, and design optimization of the DPS. They also expressed willingness to interact with messaging contingent on DPS recorded ingestion patterns. These data demonstrate that MSM who use substances find the DPS to be an acceptable method to measure and record PrEP adherence.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisSexual and Gender MinoritiesElectronicsHomosexuality, MaleHumansMaleMedication AdherenceAnti-HIV AgentsDigital pill systemHIV preventionIngestible sensorsPrEPTechnology

Identifiers

PMID33219877
PMCPMC8084862
OpenAlexW3098550058

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.